🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522541-21-00
Completed Phase I

A Phase 1 Study to Assess Radiation Biodistribution, Dosimetry, Pharmacokinetics and Safety of GEH300079 (68Ga) Injection and Determine the Optimal Injected Activity and Timing of PET/CT Imaging in Patients with Peritoneal Carcinomatosis of Colorectal, Gastric, Pancreatic or Ovarian Origin

2025-522541-21-00 · tracked via the Priya Life Science EU tracker
Sponsor
GE Healthcare Limited
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
24/02/2026
Enrollment target
16
Sites
Sweden

Condition studied

Peritoneal Carcinomatosis of Colorectal,Gastric, Pancreatic or Ovarian Origin

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522541-21-00 on CTIS ↗ ← All trials in the EU